Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Breast Neoplasms 39Ovarian Neoplasms 32Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Fallopian Tube Neoplasms 16Neoplasm Metastasis 14Pancreatic Neoplasms 9Neoplasms 9Endometrial Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Glioma 6Stomach Neoplasms 5Sarcoma 5Lung Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Ovarian Epithelial 4Solid Tumors 3Recurrence 3Osteosarcoma 3Neuroendocrine Tumors 3Lymphoma, Non-Hodgkin 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms, Castration-Resistant 2

Interventions

pembrolizumab 137Cisplatin 75Cetuximab 51Carboplatin 49Paclitaxel 39Nivolumab 38Radiotherapy 37Docetaxel 34Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 25Specimen Handling 20Fluorouracil 20Platinum 141,2-diaminocyclohexaneplatinum II citrate 13Taxes 12cemiplimab 11Radiation 11Ipilimumab 11atezolizumab 10Surgical Procedures, Operative 10Drug Therapy 10Biopsy 9durvalumab 8Radiosurgery 8130-nm albumin-bound paclitaxel 8tislelizumab 7Standard of Care 7Chemoradiotherapy 7Albumin-Bound Paclitaxel 7Immune Checkpoint Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × olaparib × 1 year × Clear all
NCT02308072 2026-05-22

ORCA-2

University College, London

Phase 1 Completed
16 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03085147 2026-02-12

A Dye for the Detection of Cancer of the Tongue and Mouth

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
23 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Washington University School of Medicine

Phase 2 Active not recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡